Sarepta Therapeutics Inc (SRPT)

Muscular Dystrophy, Duchenne · registered primary completion 2026-10-31 · NCT03992430

Published 2026-09-02Market cap $2,203M6 sourced statements

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) · PHASE3 · n=160 · active not recruiting

Share count and dilution

fact

105,627,021 shares outstanding against 133,471,021 if every outstanding option, warrant and convertible were exercised. In that case 20.9% of a gain in enterprise value would accrue to those holders rather than to current shareholders.

Source: antidilutive-securities disclosure, 10-Q filed 2026-08-05

Market

fact

No approved product carries Muscular Dystrophy, Duchenne on label.

Source: FDA label index

Trial registry

fact

Registered design for NCT03992430: randomized, quadruple-masked, 160 participants (actual). Primary outcome: Part 1: Incidence of Adverse Events (AEs). 2 further primary outcome(s) registered.

Source: ClinicalTrials.gov record

Regulatory

fact

Designations disclosed: RMAT, Breakthrough Therapy, Fast Track, Orphan Drug, Priority Review Voucher. These accelerate review and, for Orphan, confer exclusivity if approved; none is evidence of efficacy.

Source: 10-Q filed 2026-08-05

Pipeline

fact

11 distinct molecules in 10 active company-sponsored trials; delandistrogene moxeparvovec accounts for 3 of them at Phase 1/Phase 3.

Source: ClinicalTrials.gov, company as lead sponsor

Ownership and proceedings

fact

Directors and executive officers as a group hold 6.9%.

Source: DEF 14A filed 2026-04-24

Don't see a name? Request a sheet. Any US-listed biotech with a Phase 3 or a pending FDA decision — it gets built the same way, from the filings.

This sheet is dated and will not be edited. When the registered primary completion passes, its outcome is recorded on the scoreboard and a new dated sheet is published if the filings change materially.